Breaking News, Collaborations & Alliances

Baxter, Novavax Ink Sterile Manufacturing Agreement

CMO Baxter will help increase commercial production and promote access to Novavax' Covid-19 vax in UK and European markets.

By: Contract Pharma

Contract Pharma Staff

Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant. Baxter BioPharma Solutions is a contract manufacturing organization (CMO) that specializes in parenteral (injectable) pharmaceuticals, including vaccines. The agreement is expected to advance commercial-scale manufacturing essential for the vaccine’s production and distribution in the UK and Europe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters